The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

When you have diabetes, it’s important to watch out for other serious health problems that can come along with it. Eye disease is a common condition that happens with diabetes. Blood sugar ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

Doctors treat diabetic macular edema (DME) in two ways. First, they tackle what's causing it, like high blood sugar or high blood pressure. Just keeping your levels close to normal can stop eye ...

“Vabysmo has been shown to be an effective first-line treatment for diabetic macular edema, and for the first time, we now ...

diabetic macular edema and age-related macular degeneration. The prevalence of many of these serious disorders is rising. Eyes with vitreomacular adhesion-related disorders can experience rapid ...

Researchers led by the University Hospital Zurich have identified cases of sterile intraocular inflammation, including severe retinal vasculitis, associated with faricimab injections used to treat ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024Ophthalmology Innovation Summit XIV, November 23, 2024MELBOURNE, ...

a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E™, for patients with diabetic macular edema (DME). DURAVYU 2.7mg demonstrated an early, sustained, and clinically ...

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing ...